T36.AX5DAdverse effect of fluoroquinolone antibiotics, subsequent encounter

T36.AX5D is the ICD-10-CM diagnosis code for adverse effect of fluoroquinolone antibiotics, subsequent encounter. It belongs to category T36 (poisoning by, adverse effect of and underdosing of systemic antibiotics), block T36-T50 (poisoning by, adverse effects of and underdosing of drugs, medicaments and biological substances) and chapter 19 (injury, poisoning and certain other consequences of external causes). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

The 7th character "D" means subsequent encounter: use it for encounters after active treatment, while the patient is healing or recovering.

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 949 (Aftercare with CC/MCC, relative weight 1.123) and DRG 950 (Aftercare without CC/MCC, relative weight 0.7664), in MDC 23 (Factors Influencing Health Status and Other Contacts with Health Services), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.

It is exempt from present-on-admission (POA) reporting, so no POA indicator is required.

It was added in FY2026, effective October 1, 2025.